Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new rice could tame blood sugar spikes in prediabetes

NCT ID NCT07762768

Disease control Sponsor: Diabetes Foundation, India Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether a specially developed high-protein, low-glycemic index rice can improve blood sugar control in adults with prediabetes. Participants will eat both this special rice and conventional rice in a crossover design, allowing each person to serve as their own control. Researchers will measure blood sugar, insulin, and hunger responses after meals, and track glucose over 72 hours. The goal is to see if this rice variety offers a practical dietary approach to managing prediabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CSIR-developed high-protein, low-glycaemic index rice
What this could lead to
If effective, this rice could offer a simple dietary tool to help people with prediabetes manage blood sugar spikes and potentially reduce progression to diabetes.
What could go wrong
This is a small early-stage trial, so results may not apply broadly. The rice's effect on long-term diabetes prevention remains unproven, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-60 years * Individuals with prediabetes, defined by oral glucose tolerance test (OGTT) as: * Fasting plasma glucose ≥100 mg/dL and \<126 mg/dL, and/or * 2-hour plasma glucose ≥140 mg/dL and \<200 mg/dL following ingestion of 75 g anhydrous glucose * Willingness to participate and comply with study procedures Exclusion Criteria: * Diagnosed diabetes mellitus * Acute infections or any debilitating illness * History of hepatic, pancreatic, renal, or cardiovascular disease * Abnormal liver or renal function tests * Recent (\<3 months) weight change ≥5% or use of weight-altering medications * Use of glucose-lowering medications * Pregnancy or lactation * Known allergy or intolerance to study foods * Any condition that, in the investigator's opinion, may interfere with study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Diabetes, Obesity and Cholesterol Foundation (N-DOC)

    New Delhi, National Capital Territory of Delhi, 110016, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.